Recent progress in the development of agonists and antagonists for melatonin receptors

Current Medicinal Chemistry

Volumn 19, Issue 21, 2012, Pages 3532-3549

  Zlotos, D P ^a  

^a German University in Cairo   (Egypt)

Author keywords

Insomnia; Melatonin; Melatonin receptor agonists; Melatonin receptor antagonists; Melatonin receptor partial agonists; MT1 receptors; Selective ligands; Sleep disorders

Indexed keywords

5 HYDROXYETHOXY N ACETYLTRYPTAMINE; AGOMELATINE; LUZINDOLE; LY 156735; MCA NAT; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; N (2,4 DINITROPHENYL) 5 METHOXYTRYPTAMINE; PD 6735; RAMELTEON; S 22153; TASIMELTEON; TIK 301; UCM 765; UNCLASSIFIED DRUG;

BINDING AFFINITY; BINDING SITE; CIRCADIAN RHYTHM; DRUG SELECTIVITY; HUMAN; NONHUMAN; PROTEIN FUNCTION; REVIEW;

EID: 84863730090     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801323153     Document Type: Review

References (98)

1. Barrenetxe, J.; Delagrange, P.; Martinez, J.A. Physiological and metabolic functions of melatonin. J. Physiol. Biochem., 2004, 60, 61-72.
2. Pevet, P.; Bothorel, B.; Slotten, H.; Saboureau, M. The chronobiotic properties of melatonin. Cell Tissue Res., 2002, 309, 183-191.
3. Genovese, T.; Mazzon, E.; Muia, C.; Bramanti, P.; De Sarro, A.; Cuzzocrea, S. Attenuation in the evolution of experimental spinal cord trauma by treatment with melatonin. J. Pineal Res., 2005, 38, 198-208.
4. Peres, M.F.P. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia, 2005, 25, 403-411.
5. Iuvone, P.M.; Tosini, G.; Pozdeyev, N.; Haque, R.; Klein, D.C.; Chaurasia, S.S. Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina. Prog. Retinal Eye Res., 2005, 24, 433-456.
6. Sewerynek, E. Melatonin and the cardiovascular system. Neuroendocrinol. Lett., 2002, 23 (S1), 79-83.
7. (a) Witt-Enderby, P.A.; Radio, N.M.; Doctor, J.S.; Davis, V.L. Therapeutic Treatments Potentially Mediated by Melatonin Receptors: Potential Clinical Uses in the Prevention of Osteoporosis Cancer and as an Adjuvant Therapy. J. Pineal Res. 2006, 41, 297-305
8. (b) Blask, D.E.; Sauer, L.A.; Dauchy, R.T. Melatonin as a chronobiotic/anticancer agent: Cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr. Top. Med. Chem., 2002, 2, 113-132
9. (c) Mills, E.; Wu, P.; Seely, D.; Guyatt, G. Melatonin in the treatment of cancer: A systematic review of randomized controlled trials and metaanalysis. J. Pineal Res., 2005, 39, 360-366.
10. Sofic, E.; Rimpapa, Z.; Kundurovic, Z.; Sapcanin, A.; Tahirovic, I; Rustembegovic, A.; Cao, G. Antioxidant capacity of the neurohormone melatonin. J. Neural Transm., 2005, 112, 349-358.
11. Macleod, M.R.; O'Collins, T; Horky, L.L.; Howells, D.W.; Donnan, G.A. Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J. Pineal Res., 2005, 38, 35-41.
12. Srinivasan, V.; Pandi-Perumal, S.; Cardinali, D.; Poeggeler, B.; Hardeland, R. Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav. Brain Funct., 2006, 2 (No pp given)
13. (b) Medeiros, C.A. M.; Carvalhedo de Bruin, P.F.; Lopes, L.A.; Magalhães, M.C.; Seabra, M.de L.; Sales de Bruin, V.M. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. J. Neurol, 2007, 254, 459-464.
14. Reppert, SM.; Weaver, D.R.; Godson, C. Melatonin receptors step into the light: Cloning and classification of subtypes. Trends Pharmacol. Sci., 1996, 17, 100-102.
15. Nosjean, O.; Ferro, M.; Coge, F.; Beauverger, P.; Henlin, J.M.; Lefoulon, F.; Fauchere, J.L.; Delagrange, P.; Canet, E.; Boutin, J.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol Chem., 2000, 275, 31311-31317.
16. Li, P.-K.; Witt-Enderby, P.A. Melatonin receptors as potential targets for drug discovery. Drug Future, 2000, 25, 945-957.
17. 2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J., 1998, 12, 1211-1220.
18. Liu, C; Weaver, D.R.; Jin, X.; Shearman, L.P; Pieschl, R.L.; Gribkoff, V.K.; Reppert, SM. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron, 1997, 19, 91-102.
19. Doolen, S.; Krause, D.N.; Dubocovich, M.L.; Duckles, S.P. Melatonin mediates two distinct responses in vascular smooth muscle. Eur. J. Pharmacol, 1998, 345, 67-69.
20. Hunt, A.E.; Al-Ghoul, W.M.; Gillette, M.U.; Dubocovich, M.L. Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am. J. Physiol, 2001, 280, C110-C118.
21. Dubocovich, M.L.; Markowska, M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine, 2005, 27, 101-110.
22. Hardeland, R. New approaches in the management of insomnia: weighing the advantages of prolonged release melatonin and synthetic melatoninerg ic agonists. Neuropsychiatr Dis Treat., 2009, 5, 341-354.
23. Gershell, L. Insomnia market. Nature Rev. Drug Discov., 2006, 5, 15-17.
24. Pandi-Perumal, S.R.; Srinivasan, V; Poeggeler, B.; Hardeland, R.; Cardinali, D.P Drug insight: The use of melatonergic agonists for the treatment of insomnia-Focus on ramelteon. Nat. Clin. Pract. Neurol, 2007, 3, 221-228.
25. 11C] Ramelteon as a Positron Emission Tomography Probe for Imaging Melatonin Receptors Involved in Circadian Rhythms. Chem. Pharm. Bull, 2011, 59, 1062-1064.
26. de Bodinat, C; Guardiola-Lemaitre, B.; Mocaër, E.; Renard, P.; Muñoz, C; Millan, M.J. Agomelatine, the first melatonergic antidepressant: discovery characterization and development. Nat. Rev Drug Discov., 2010, 9, 628-642.
27. Zemlan, FP; Mulchahey, J.J.; Scharf, M.B.; Mayleben, D.W.; Rosenberg, R.; Lankford, A. The efficacy and safety of the melatonin agonist ß-methyl-6-chloromelatonin in primary insomnia: A randomized, placebo-controlled, crossover clinical trial. J. Clin. Psychiatry, 2005, 66, 384-390.
28. Lankford, D.A. Tasimelteon for insomnia Expert Opin Investig Drugs, 2011, 20, 987-93.
29. Landolt, H.P; Wehrle, R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci., 2009; 29, 1795-1809.
30. Mody, SM.; Hu, Y.; Ho, M.K.C., Wong, YH. In Search of Novel and Therapeutically Significant Melatoninerg ic Ligands. Recent Patents on CNS Drug Discovery, 2007, 2, 241-245.
31. Rivara, S.; Mor, M.; Bedini, A.; Spadoni, G.; Tarzia, G. Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders. Curr Top Med Chem., 2008, 8, 954-968.
32. 2 receptor agonists. Expert Opin. Ther. Petents, 2010, 20(8), 1059-1077.
33. Hardeland, R.; Investigational melatonin receptor agonists. Exp. Opin. Investig. Drugs, 2010, 19, 747-764.
34. 2 but not MT1 melatonin receptors. J. Pineal Res., 2005, 39, 170-177.
35. Li, X.M.; Beau, J.; Delagrange, P.; Mocaer, E.; Lévi, F. Circadian rhythm entrainment with melatonin, melatonin receptor antagonist S22153 or their combination in mice exposed to constant light. J. Pineal Res., 2004, 37, 176-184.
36. Willis, G.L. The role of ML-23 and other melatonin analogs in the treatment and management of Parkinson's disease. Drug News Perspect, 2005, 18, 437-44.
37. Zlotos, D. P. Recent advances in melatonin receptor ligands. Arch. Pharm. Chem. Life Sci., 2005, 338, 229-247.
38. Spadoni, G.; Bedini, A. Advances on the development of subtype selective melatonin ligands. In Melatonin: From Molecules to Therapy, Pandi-Perumal, S. R.; Cardinali, D.P; Nova Scotia Publishers Inc., Hauppauge, 2007, pp-33-45.
39. Garratt, P.J.; Tsotinis, A. Synthesis of Compounds as Melatonin Agonists and Antagonists. Mini Rev. Med. Chem., 2007, 7, 1075-1088.
40. nd ed (Girdlestone D ed) pp 270-277. IUPHAR Media, London.
41. Garratt, P.J.; Travard, S.; Vonhoff, S.; Tsotinis, A.; Sugden, D. Mapping the Melatonin Receptor. 4. Comparison of the Binding Affinities of a Series of Substituted Phenylalkyl Amides. J. Med. Chem., 1996 39, 1797-1805.
42. Carocci, A.; Catalano, A.; Lovece, A.; Lentini, G.; Duranti, A.; Lucini, V; Pannacci, M.; Scaglione, F; Franchini, C. Design, synthesis, and pharmacological effects of structurally simple ligands for MT1 and MT2 melatonin receptors. Bioorg. Med. Chem., 2010, 18, 6496-6551.
43. Tsotinis, A.; Vlachou, M.; Papahatjis, D.P; Calogeropoulou, T.; Nikas, S.P; Garratt, P.J.; Piccio, V; Vonhoff, S.; Davidson, K.; Teh, M.T.; Sugden, D. Mapping the Melatonin Receptor. 7. Subtype Selective Ligands Based on ß-Substituted N-Acyl-5-methoxytryptamines and N-Acyl-5-methoxy-1-methyl- tryptamines. J. Med. Chem., 2006, 49, 3509-3519.
44. Tsotinis, A.; Panoussopoulou, M.; Eleutheriades, A.; Davidson, K.; Sugden, D. Design, synthesis and melatoninerg ic potency of new N-acyl 8, 9-dihydro-4-methoxy-7H-2-benzo[de] quinolinalkanamines. Eur. J. Med. Chem., 2007, 42, 1004-1013.
45. Tsotinis, A.; Eleutheriades, A.; Hough, K.A.; Davidson, K.; Sugden, D. Design, synthesis and melatonin erg ic activity of new unsubstituted and ß, ß-difunctionalised 2, 3-dihydro-1 H-pyrrolo[3, 2, 1-ij] quino lin-6-alk an amides. Bioorg. Chem., 2007, 35, 189-204.
46. 2-selective melatonin receptor ligands. Bioorg. Med. Chem., 2009, 52, 826-833.
47. Attia, M.I.; Julius, J.; Witt-Enderby, P.A.; Zlotos, D.P. Synthesis and pharmacological evaluation of 13a, 14-dihydro-6H, 13H-pyrazino [1, 2-a;4, 5-á] diindole analogs as melatonin receptor ligands. Tetrahedron, 2007, 63, 754-760.
48. Attia, M.I; Witt-Enderby, P.A.; Julius, J. Synthesis and pharmacological evaluation of pentacyclic 6a, 7-dihydrodiindole and 2, 3-dihydrodiindole derivatives as novel melatoninerg ic ligands. Bioorg. Med. Chem., 2008, 16, 7654-7661.
49. Attia, M.I.; Güclü, D.; Hertlein, B.; Julius, J.; Witt-Enderby, P.A.; Zlotos, D.P. Synthesis, NMR conformational analysis and pharmacological evaluation of 7, 7a, 13, 14-tetrahydro-6H-cyclobuta[b]pyrimido[1, 2-a:3, 4-á]diindole analogs as melatonin receptor ligands. Org. Biomol Chem., 2007, 5, 2129-2137.
50. Zefirova, O.N.; Baranova, T.Y; Ivanova, A.A.; Ivanov, A.A.; Zefirov, N.S. Application of the bridgehead fragments for the design of conformationally restricted melatonin analogs. Bioorg. Chem., 2011, 39, 67-72.
51. Faust, R.; Garratt, P.J.; Trujillo Pèrez, M.A., Piccio, V.J.D.; Madsen, C; Stenstrom, A.; Frolund, B.; Davidson, K.; Teh, M.T.; Sugden, D. 7-Substituted-melatonin and 7-substituted-1-methylmelatonin analogs: Effect of substituents on potency and binding affinity. Bioorg. Med. Chem., 2007, 15, 4543-4551.
52. Leclerc, V; Said, Y; Delagrange, P.; Boutin, J.A.; Renard, P.; Lesieur, D. Synthesis of Nitroindole Derivatives with High Affinity and Selectivity for Melatoninerg ic Binding Sites MT3. J. Med. Chem., 2002, 45, 1853-1859.
53. Tsotinis, A.; Eleutheriades, A.; Hough, K.; Sugden, D. Design and synthesis of potent N1-substituted indole melatonin receptor agonists. Chem. Comm., 2003, 382-383.
54. Tsotinis, A.; Gourgourinis, J.; Eleutheriades, A.; Davidson, K.; Sugden, D. Design and Synthesis of New N-OMe Fluoro-Indole Melatoninergics. Med. Chem., 2007, 3, 561-571.
55. Tsotinis, A.; Eleutheriades, A.; Davidson, K.; Sugden, D. Design and Synthesis of New N-OMe Fluoro-Indole Melatoninergics. Curr. Drug Discov. Techn., 2007, 4, 198-207.
56. Rivara, S.; Diamantini, G.; Di Giacomo, B.; Lamba, D.; Gatti, G.; Lucini, V.; Pannacci, M.; Mor, M.; Spadoni, G.; Tarzia, G. Reassessing the melatonin pharmacophore-Enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analog. Bioorg. Med. Chem., 2006, 14, 3383-3391.
57. Di Giacomo, B.; Bedini, A.; Spadoni, G.; Tarzia, G.; Fraschini, F.; Pannacci, M.; Lucini, V. Synthesis and biological activity of new melatonin dimeric derivatives. Bioorg. Med. Chem., 2007, 15, 4643-4650.
58. Elsner, J.; Boeckler, F.; Davidson, K.; Sugden, D.; Gmeiner, P. Bicyclic melatonin receptor agonists containing a ring-junction nitrogen: Synthesis, biological evaluation, and molecular modelling of the putative bioactive conformation. Bioorg. Med. Chem., 2006, 14, 1949-1958.
59. El Kazzouli, S.; du Bellay, A.G.; Berteina-Raboin, S.; Delagrange, Philippe.; Caignard, D.H.; Guillaumet, G. Design and synthesis of 2-phenylimidazo[1, 2-a]pyridines as a novel class of melatonin receptor ligands. Eur. J. Med. Chem., 2011, 46, 4252-4257.
60. Jeanty, M.; Suzenet, F.; Delagrange, F.; Nosjean, O.; Boutin, J.A.; Caignard, D.H.; Guillaumet, G. Design and synthesis of 1-(2-alkanamidoethyl)-6- methoxy-7-azaindolederivatives as potent melatonin agonists. Bioorg. Med. Chem. Lett., 2011, 21, 2316-2319.
61. Tarzia, G.; Diamantini, G.; Di Giacomo, B.; Spadoni, G.; Esposti, D.; Nonno, R.; Lucini, V.; Pannacci, M.; Fraschini, F.; Stankov, B. M. 1-(2-Alkanamidoethyl)-6-methoxyindole Derivatives: a New Class of Potent Indole Melatonin Analogs. J. Med. Chem., 1997, 40, 2003-2010.
62. 2-Selective Agonists J. Med. Chem., 2011, 54, 3436-3444.
63. Koike, T.; Takai, T.; Hoashi, Y.; Nakayama, M.; Kosugi, Y.; Nakashima, M.; Yoshikubo, S.; Hirai, K.; Uchikawa, O. Synthesis of a Novel Series of Tricyclic Dihydrofuran Derivatives: Discovery of 8, 9-Dihydrofuro [3, 2-c] pyrazolo [1, 5-a] pyridines as Melatonin Receptor (MT1/MT2) Ligands. J. Med. Chem., 2011, 54, 4207-4218.
64. Leeson, P. D.; Springthorpe, B. The Influence of Drug-like Concepts on Decision-Making in Medicinal Chemistry. Nat. Rev. Drug Discovery, 2007, 6, 881-890.
65. Koike, T.; Hoashi, Y.; Takai, T.; Uchikawa, O. Synthesis of 4-aza analog of ramelteon: a novel tricyclic 1, 6, 7, 8-tetrahydro-2H-cyclopenta [d] furo [2, 3-b] pyridine derivative as melatonin receptor ligand. Tetrahedron Lett., 2011, 52 3009-3011.
66. Li, G.; Zhou, H.; Jiang, Y.; Keim, H.; Topiol, S.W.; Poda, S.B.; Ren, Y.; Chandrasena, G.; Doller, D. Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carboxamide derivatives as novel melatonin receptor ligands. Bioorg. Med. Chem. Lett., 2011, 21, 1236-1242.
67. Sun, L.-Q.; Chen, J.; Mattson, R.; Epperson, J. R.; Deskus, J. A.; Li, W.; Takaki, K.; Hodges, D. B.; Iben, L.; Mahle, C. D.; Ortiz, A.; Molstad, D.; Ryan, E.; Yeleswaram, K.; Xu, C.; Luo, G. Bioorg. Med. Chem. Lett., 2003, 13, 4381-4384.
68. Spadoni, G.; Bedini, A.; Guidi, T.; Tarzia, G.; Lucini, V.; Pannacci, M.; Fraschini, F. Towards the development of mixed MT1-agonist/MT2-antagonist melatonin receptor ligands. ChemMedChem, 2006, 1, 1099-1105.
69. Rivara, S.; Lodola, A.; Mor, M.; Bedini, A.; Spadoni, G.; Lucini, V.; Pannacci, M.; Fraschini, F.; Scaglione, F.; Sanchez, R.O.; Gobbi, G.; Tarzia, G. N-(Substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J. Med. Chem., 2007, 50, 6618-6626.
70. Falco, J.L.; Palomer, A. Preparation of 1-(2-alkyl-2, 3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds with affinity for melatonin receptors and use in treating melatoninergic disorders, Ferrer Internacional WO 2010145989, 2010.
71. Nonno, R.; Lucini, V.; Spadoni, G.; Pannacci, M.; Croce, A.; Esposti, D.; Balsamini, C.; Tarzia, G.; Fraschini, F.; Stankov, B.M. A new melatonin receptor ligand with mt1-agonist and MT2-antagonist properties J. Pineal Res., 2000, 29, 234-240.
72. Spadoni, G.; Bedini, A.; Guidi, T., Tarzia, G.; Lucini, V.; Pannacci, M.; Fraschini, F. Towards the Development of Mixed MT1-Agonist/MT2-Antagonist Melatonin Receptor Ligands ChemMedChem, 2006, 1, 1099-1105.
73. Spadoni, G.; Bedini, A.; Diamantini, G.; Tarzia, G.; Rivara, S.; Lorenzi, S.; Lodola, A.; Mor, M.; Lucini, V.; Pannacci, M.; Caronno, A.; Fraschini, F. Synthesis, Enantiomeric Resolution, and Structure-Activity Relationship of a Series of 10, 11-Dihydro-5H-Dibenzo [a, d] cycloheptene MT2 Receptor Antagonists. ChemMedChem., 2007, 2, 1741-1749.
74. Rivara, S.; Lorenzi, S.; Mor, M.; Plazzi, P.V.; Spadoni, G.; Bedini, A.; Tarzia, G. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models. J. Med. Chem., 2005, 48, 4049-4060.
75. a) Tsotinis, A.; Afroudakis, P.A. Melatonin receptor antagonist luzindole: A facile new synthesis. Lett. Org. Chem., 2008, 5, 507-509
76. b) Dubocovich, M.L.; Masana, M.I.; Iacob, S.; Sauri, D.M. Melatonin receptor antagonists that differentiate between the human Mel1 a and Mel 1b recombinant subtypes are used to assess the pharmacological profileof the rabbit retina ML1 presynaptic heteroreceptor Naunyn-Schmiedeberg's Arch Pharmacol., 1997, 355, 365-375.
77. Lucarini, S.; Bartolucci, S.; Bedini, A.; Gatti, G.; Orlando, P.; Piersanti, G.; Spadoni, G. Synthesis and configuration determination of all enantiopure stereoisomers of the melatonin receptor ligand 4-phenyl-2- propionamidotetralin using an expedient optical resolution of 4-phenyl-2-tetralone Org. Biomol. Chem., 2012, 10, 305-313.
78. Bedini, A.; Lucarini, S.; Spadoni, G.; Tarzia, G.; Scaglione, F.; Dugnani, S.; Pannacci, M.; Lucini, V.; Carmi, C.; Pala, D.; Rivara, S.; Mor, M. Toward the Definition of Stereochemical Requirements for MT2-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. J. Med. Chem., 2011, 54, 8362-8372.
79. Durieux, S.; Chanu, A.; Bochu, C.; Audinot, V.; Coumailleau, S.; Boutin, J.A.; Delagrange, P.; Caignard, D.H.; Bennejean, C.; Renard, P.; Lesieur, D.;.Berthelot, P.; Yous, S. Design and synthesis of 3- phenyltetrahydronaphthalenic derivatives as new selective MT2 melatonin erg ic ligands. Part II Bioorg. Med. Chem., 2009, 17, 2963-2974.
80. 2 melatonin receptor selective ligands. J. Med. Chem., 2002, 45, 2788-2800.
81. 2 melatonin erg ic ligands. Bioorg. Med. Chem., 2008, 16, 8339-8348.
82. Audinot, V.; Mailliet, F.; Lahaye-Brasseur, C.; Bonnaud, A.; Le Gall, A.; Amossé, C.; Dromaint, S.; Rodriguez, M.; Nagel, N; Galizzi, j.P; Malpaux, B.; Guillaumet, G.; Lesieur, D.; Lefoulon, F.; Renard, P.; Delagrange, P.; Boutin, J.A. Naunyn-Schmiedeberg's Arch. Pharmacol, 2003, 367, 553-561.
83. 2-selective melatonin receptor ligands. J. Med. Chem., 2006, 49, 7393-7403.
84. Ochoa-Sanchez, R.; S. Comai, Lacoste, B.; Bambico, F.R.; Dominguez-Lopez, S.; Spadoni, G.; Rivara, S.; Bedini, A.; Angeloni, D.; Fraschini, F.; Mor, M.; Tarzia, G.; Descarries, L.; Gobbi, G. Promotion of Non-Rapid Eye Movement Sleep and Activation of Reticular Thalamic Neurons by a Novel MT2 Melatonin Receptor Ligand J. Neurosci., 2011, 31, 18452-18439.
85. Hu, Y; Ho, M. K.C.: Chan, K.H.; New, D.C.; Wong, YH. Synthesis of substituted N-[3-(3-methoxyphenyl)propyl]. amides as highly potent MT2-selective melatonin ligands, Bioorg. Med. Chem. Lett, 2010, 20, 2582-2585.
86. 2-selective melatonin receptor antagonist. Med. Chem. Commun., 2011, 2, 991-994.
87. Zhu, J.; Hu, Y; Ho, M.K.C.; Wong, YH. 3-Methoxylphenylpropyl amides as novel receptor subtype-selective melatonin erg ic ligands: characterization of physicochemical and pharmacokinetic properties. Xenobiotica, 2011; 41, 35-45.
88. Zlotos, D.P; Attia, M.I.; Julius, J.; Sethi, S.; Witt-Enderby, P.A. 2-[(2, 3-Dihydro-1 H-indol-1-yl)methyl] melatonin Analogs: A Novel Class of MT2-Selective Melatonin Receptor Antagonists. J. Med. Chem., 2009, 52, 826-833.
89. Mésangeau, C; Fraise, M.; Delagrange, P.; Caignard, D.H.; Boutin, J.A.; Berthelot, P.; Yous, S. Preparation and pharmacological evaluation of a novel series of 2-(phenylthio) benzo [b] thiophenes as selective MT2 receptor ligands. Eur. J. Med. Chem., 2011, 46, 1835-1840.
90. Descamps-Francois, C; Yous, S.; Chavatte, P.; Audinot, V.; Bonnaud, A.; Boutin, J.A.; Delagrange, P.; Bennejean, C; Renard, P.; Lesieur, D. Design and Synthesis of Naphthalenic Dimers as Selective MT1 Melatoninerg ic Ligands. J. Med. Chem., 2003, 46, 1127-1129.
91. Sun, L.Q.; Chen, J.; Bruce, M.; Deskus, J.A.; Epperson, J.R.; Takaki, K.; Johnson, G.; Iben, L.; Mahle, CD.; Ryan, E.; Xu, C. Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg. Med. Chem. Lett., 2004, 14, 3799-3802.
92. Mesangeau, C; Peres, B.; Descamps-Francois, C; Chavatte, P.; Audinot, V.; Coumailleau, S.; Boutin, J.A.; Delagrange, P.; Bennejean, C; Renard, P.; Caignard, D.H.; Berthelot, P.; Yous, S. Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT1 melatoninerg ic ligands Bioorg Med Chem., 2010, 18, 3426-3436.
93. Markl, C; Clafshenkel, W. P.; Attia, M. I; Sethi, S.; Witt-Enderby, P. A.; Zlotos, D. P. N-Acetyl-5-arylalkoxytryptamine Analogs: Probing the Melatonin Receptors for MT1-Selectivity Arch. Pharm. Chem. Life. Sci., 2011, 334, 666-674.
94. Spadoni, G.; Bedini, A.; Orlando, P.; Lucarini, S.; Tarzia, G.; Mor, M.; Rivara, S.; Lucini, V.; Pannacci, M.; Scaglione, F. Bivalent ligand approach on N-{2-[(3-methoxyphenyl)methylamino]ethyl}-acetamide: Synthesis, binding affinity and intrinsic activity forMT1 and MT2 melatonin receptors. Bioorg. Med. Chem., 2011, 19, 4910-4916.
95. Ettaoussi, M.; Peres, B.; Klupsch, F.; Delagrange, P.; Boutin, J.A.; Renard, P.; Caignard, D.H.; Chavatte, P.; Berthelot, P.; Lesieur, D.; Yous, S. Design and synthesis of benzofuranic derivatives as new ligandsat the melatonin-binding site MT3. Bioorg. Med. Chem., 2008, 16, 4954-4962.
96. Leclerc, V.; Ettaoussi, M.; Rami, M.; Farce, A.; Boutin, J.A.; Delagrange, P.; Caignard, D.H.; Renard, P.; Berthelot, P.; Yous, S. Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3. Eur. J. Med. Chem., 2011, 46, 1622-1629.
97. Boussard, M.F.; Truche, S.; Rousseau-Rojas, A.; Briss, S.; Descamps, S.; Droual, M.; Wierzbicki, M.; Ferry, G.; Audinot, V.; Delagrange, P.; Boutin, J.A. New ligands at the melatonin binding site MT3. Eur. J. Med. Chem., 2006, 41, 306-320.
98. Pegan S.D.; Sturdy, M.; Ferry, G.; Delagrange, P.; Boutin, J.A.; Mesecar, A. D. X-ray structural studies of quinine reductase 2 nanomolar range inhibitors. Protein Science, 2011, 20, 1182-1195.